5-磷酸吡哆醛

5-磷酸吡哆醛用途

Pyridoxal 5'-phosphate hydrate 是维生素 B6 的活性形式,它是多种酶 (包括可催化神经递质多巴胺和5-羟色胺生产的最后阶段的芳族 L-氨基酸脱羧酶) 的重要辅因子。Pyridoxal 5'-phosphate hydrate 是维生素 B6 在细胞内磷酸化过程中最重要的辅酶变异体,可与其他变异体互换,包括 PNP 和 PMP。

5-磷酸吡哆醛名称

[ CAS 号 ]:
41468-25-1

[ 中文名 ]:
5-磷酸吡哆醛

[ 英文名 ]:
Pyridoxal 5'-phosphate monohydrate

[中文别名 ]:

[英文别名 ]:

Pyridoxal 5‘-phosphate monohydrate
5-Phosphate Monohydrate
PYRIDOXAL-5-PHOSPHATE H2O
EINECS 200-208-3
phosphopyridoxalmonohydrate
MFCD00149414
Pyridoxal 5-phosphate
Codecarboxylase Monohydrate
pyridoxylphosphatemonohydrate
PLP

5-磷酸吡哆醛生物活性

[ 描述 ]:

[ 相关类别 ]:

研究领域 >> 其他

信号通路 >> 其他 >> 其他

[ 靶点 ]

IC50: active form of vitamin B6[1]

[参考文献]

[1]. Allen GF, et al. Pyridoxal 5'-phosphate deficiency causes a loss of aromatic L-amino acid decarboxylase in patients and human neuroblastoma cells, implications for aromatic L-amino acid decarboxylase and vitamin B(6) deficiency states.J Neurochem. 2010 Jul;114(1):87-96.

[2]. Calderón-Ospina CA, et al. B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin.CNS Neurosci Ther. 2020 Jan;26(1):5-13.

5-磷酸吡哆醛物理化学性质

[ 沸点 ]:
565.7ºC at 760 mmHg

[ 熔点 ]:
140-143 °C(lit.)

[ 分子式 ]:
C₈H₁₂NO₇P

[ 分子量 ]:
265.157

[ 闪点 ]:
296ºC

[ 精确质量 ]:
265.035126

[ PSA ]:
135.99000

[ LogP ]:
0.45310

[ 外观性状 ]:
略黄色粉末

[ 储存条件 ]:
2-8°C

[ 水溶解性 ]:
5 g/L (20 ºC)

5-磷酸吡哆醛MSDS

详细MSDS(安全技术说明书)

5-磷酸吡哆醛毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UV1208000

CHEMICAL NAME :: Pyridoxal, 5-(dihydrogen phosphate), monohydrate

CAS REGISTRY NUMBER :: 41468-25-1

LAST UPDATED :: 199504

DATA ITEMS CITED :: 6

MOLECULAR FORMULA :: C8-H10-N-O6-P.H2-O

MOLECULAR WEIGHT :: 265.18

WISWESSER LINE NOTATION :: T6NJ B1 CQ DVH E1OPQQO &QH

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 5900 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Behavioral - excitement

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 11,922,1961

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 850 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Behavioral - excitement

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 11,922,1961

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 4640 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 11,922,1961

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 870 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 11,922,1961

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 250 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Gastrointestinal - changes in structure or function of salivary glands Gastrointestinal - hypermotility, diarrhea

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 11,922,1961 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X2669 No. of Facilities: 42 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 243 (estimated) No. of Female Employees: 243 (estimated)

5-磷酸吡哆醛安全信息

[ 个人防护装备 ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ 危害码 (欧洲) ]:
Xi: Irritant;

[ 风险声明 (欧洲) ]:
R36/37/38

[ 安全声明 (欧洲) ]:
S24/25

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
2

[ RTECS号 ]:
UV1208000

[ 海关编码 ]:
2936250000

5-磷酸吡哆醛制备

生产方法简述；以吡哆醇为原料

5-磷酸吡哆醛海关

[ 海关编码 ]: 2933399090

[ 中文概述 ]:
2933399090. 其他结构含非稠合吡啶环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

5-磷酸吡哆醛文献

Epidermal axonal swellings in painful and painless diabetic peripheral neuropathy.

Muscle Nerve 51(4) , 505-13, (2015)

The pathophysiology of neuropathic pain (NeP) in diabetic peripheral neuropathy (DPN) is unclear. A potential pathological feature associated with intraepidermal nerve fiber density (IENFD) loss in DP...

Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders.

J. Neuropathol. Exp. Neurol. 74 , 1093-118, (2015)

Despite effective viral suppression through combined antiretroviral therapy (cART), approximately half of HIV-positive individuals have HIV-associated neurocognitive disorders (HAND). Studies of antir...

Four different synthetic peptides of proteolipid protein induce a distinct antibody response in MP4-induced experimental autoimmune encephalomyelitis.

Clin. Immunol. 159 , 93-106, (2015)

Here we studied the autoantibody specificity elicited by proteolipid protein (PLP) in MP4-induced experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis (MS). In C57BL/6 (B6) m...

更多文献